Top Gene Editing Companies in Singapore

Macrogen APAC, a subsidiary of Macrogen, Inc., is a leading provider of genomics services, including Next Generation Sequencing (NGS) and CRISPR products, which are essential tools in gene editing research and applications. Their advanced sequencing techniques support both research and clinical diagnostics, highlighting their expertise in precision medicine and genomic analysis.

1010Genome is at the forefront of genomics, specializing in Next-Generation Sequencing (NGS) and advanced bioinformatics solutions, which are crucial for gene editing research. Their services support various sequencing technologies and enable researchers to make significant discoveries in healthcare and scientific understanding, including structural variation identification and differential gene expression analysis.

CellVec is a certified GMP gene therapy CDMO that specializes in providing custom viral vectors for pre-clinical and clinical applications, highlighting its expertise in gene editing. With a state-of-the-art GMP manufacturing facility and a focus on overcoming production bottlenecks, CellVec develops innovative gene transfer technologies to advance therapeutic products from bench to bedside.

Genedant is focused on investing in emerging science and technology ventures, particularly in the biomedical sector, which aligns with innovative approaches like gene editing. They support early-stage deep-tech startups that seek to challenge the status quo and drive significant advancements in their fields.

Hyperganic is a deep-tech company focused on engineering innovation through Algorithmic Engineering, which enhances productivity in product development. Their approach, combining geometry and simulation technologies, enables the creation of complex and functional designs that could have implications for fields like biotechnology and medical engineering.

The company is dedicated to enhancing early disease detection through the identification of genetic risk factors, which is highly relevant to gene editing. Their focus on personalized chronic disease management addresses specific health challenges, particularly for Asian populations.

Everlife-Research Instruments is dedicated to providing advanced research tools and technologies that can support the scientific community, particularly in areas like cell and gene therapy. Their commitment to innovation and efficiency enables researchers to access cutting-edge solutions that enhance their operations and meet evolving scientific needs.

Allozymes is focused on revolutionizing the manufacturing of complex natural products through its proprietary platform technology, which emphasizes the development of custom-designed enzymes. Their commitment to creating sustainable biosolutions suggests a forward-thinking approach that could align with advancements in gene editing and biocatalysis.

Tessa Therapeutics is focused on developing innovative cell therapies for cancer, including a promising allogeneic CD30-CAR EBVST platform that leverages Virus Specific T-cells to target various cancers. This approach represents a significant advancement in cancer treatment, aligning with the growing interest in gene editing and cellular modifications for therapeutic purposes.

Guardant Health AMEA is focused on precision oncology, working with pharmaceutical companies to enhance cancer treatment through innovative blood tests that provide vital molecular information. Their Guardant360® assay offers comprehensive genomic profiling, which is essential for developing targeted therapies and improving patient outcomes.